CA2095439A1 - Substance that stops any bleeding on contact for medical, surgical and dental uses - Google Patents
Substance that stops any bleeding on contact for medical, surgical and dental usesInfo
- Publication number
- CA2095439A1 CA2095439A1 CA 2095439 CA2095439A CA2095439A1 CA 2095439 A1 CA2095439 A1 CA 2095439A1 CA 2095439 CA2095439 CA 2095439 CA 2095439 A CA2095439 A CA 2095439A CA 2095439 A1 CA2095439 A1 CA 2095439A1
- Authority
- CA
- Canada
- Prior art keywords
- contact
- blood
- bleeding
- coagulation
- pathways
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000740 bleeding effect Effects 0.000 title abstract 3
- 239000000126 substance Substances 0.000 title 1
- 230000023555 blood coagulation Effects 0.000 abstract 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- 230000037361 pathway Effects 0.000 abstract 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 2
- 208000034158 bleeding Diseases 0.000 abstract 2
- 239000003114 blood coagulation factor Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010000020 Platelet Factor 3 Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000006624 extrinsic pathway Effects 0.000 abstract 1
- 230000006623 intrinsic pathway Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
There is disclosed a method for stopping bleeding and forming black blood coagulation on contact, comprising administering powdered L-threo-hex-2-enono-1,4-lactone thereof to a wound site in an amount of 0.1568 grams for every milliliter of blood. This includes cancer, liver disease and hemophiliac bleeding in patients or animals in whom the thrombocytopenia or coagulation factor disorders result. Accordingly, the said mechanism of action of powdered L-threo-hex-2-enono-1,4-lactone in the formation of blood coagulation on contact is the unique common pathway for all blood coagulations, which overturns the mechanisms of intrinsic and extrinsic pathways for blood coagulation cascade being the unique pathways for blood coagulation in which the coagulation factors 1, 2, 5, 7, 8, 9, 10 and platelet factor 3 are essential for the pathways.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62409490A | 1990-12-06 | 1990-12-06 | |
| US07/624,094 | 1990-12-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2095439A1 true CA2095439A1 (en) | 1992-06-07 |
| CA2095439C CA2095439C (en) | 1998-12-08 |
Family
ID=24500629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2095439 Expired - Fee Related CA2095439C (en) | 1990-12-06 | 1991-12-05 | Substance that stops any bleeding on contact for medical, surgical and dental uses |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0644754A4 (en) |
| AU (1) | AU662505B2 (en) |
| CA (1) | CA2095439C (en) |
| NO (1) | NO930858D0 (en) |
| WO (1) | WO1992010999A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1334933A (en) * | 1971-02-19 | 1973-10-24 | Ahrens G W | Reaction products of caldium ascorbate and preparation containing them |
| FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
| JPS6029361B2 (en) * | 1977-03-04 | 1985-07-10 | 白井松新薬株式会社 | Pharmaceutical composition with enhanced hemostatic effect |
| US4959362A (en) * | 1983-12-19 | 1990-09-25 | Takeda Chemical Industries, Inc. | Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system |
| NO161779C (en) * | 1986-04-22 | 1989-10-04 | Olav Johan Braenden | PROCEDURE FOR PREPARING AN ANTI-COOLING PREPARATION. |
| US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
| US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
-
1991
- 1991-12-05 CA CA 2095439 patent/CA2095439C/en not_active Expired - Fee Related
- 1991-12-05 AU AU91034/91A patent/AU662505B2/en not_active Ceased
- 1991-12-05 EP EP92901379A patent/EP0644754A4/en not_active Withdrawn
- 1991-12-05 WO PCT/US1991/009201 patent/WO1992010999A1/en not_active Application Discontinuation
-
1993
- 1993-03-09 NO NO1993930858A patent/NO930858D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU662505B2 (en) | 1995-09-07 |
| EP0644754A1 (en) | 1995-03-29 |
| EP0644754A4 (en) | 1995-12-27 |
| CA2095439C (en) | 1998-12-08 |
| AU9103491A (en) | 1992-07-22 |
| NO930858D0 (en) | 1993-03-09 |
| WO1992010999A1 (en) | 1992-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69016755D1 (en) | Delayed-release pharmaceutical preparation for the treatment of periodontal diseases. | |
| NL990012I1 (en) | Medicines containing salmeterol and fluticasone. | |
| EE02971B1 (en) | Use of droloxyfene or its salts in the manufacture of a medicament for the treatment of bone diseases | |
| DK0416950T3 (en) | medications | |
| EP0376251A3 (en) | An anticoagulant substance obtained from urine | |
| ATE87484T1 (en) | PHYSIOLOGICALLY ACTIVE SUBSTANCES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| ATE133859T1 (en) | SUSTAINED-RELEASE PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF PERIODONTAL DISEASES | |
| ATE198550T1 (en) | USE OF FRANKINCENSE TO TREAT ALZHEIMER'S DISEASE | |
| ATE99172T1 (en) | USE OF ACETYL-L-CARNITINE IN TREATMENT OF CATARACT, AND PHARMACEUTICAL COMPOSITIONS FOR SUCH TREATMENT. | |
| ATE88633T1 (en) | USE OF CERTAIN CALCIUM CITRATE MALATE IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS. | |
| Smith et al. | Amitriptyline and heart block | |
| ATE89737T1 (en) | TREATMENT OF LEUKOCYTE DISORDERS WITH GM-CSF. | |
| CA2095439A1 (en) | Substance that stops any bleeding on contact for medical, surgical and dental uses | |
| DK0588477T3 (en) | Medical preparation comprising TCF-11 | |
| DE69621786D1 (en) | AMINOTETRAL IN DERIVATIVE FOR THE TREATMENT OF HEART CIRCULAR DISEASE | |
| DE3380923D1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS CONDITIONED BY HUMAN DRUGS. | |
| KR900009029A (en) | Device for administering drugs for the treatment of livestock diseases | |
| ATE161016T1 (en) | PROPHYLACTIC/THERAPEUTIC COMPOSITION CONTAINING WS7622A FOR THE PREVENTION AND TREATMENT OF SCATTERED, INTRAVASCULAR COAGULATION, CHRONIC, INFECTIOUS RESPIRATORY DISEASES OR CHRONIC BRONCHITIS | |
| ATE299496T1 (en) | PYRIDINIUM COMPOUNDS FOR THE TREATMENT OF AGE-RELATED DISEASES | |
| US6783774B1 (en) | Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses | |
| ATE79750T1 (en) | ANTI-CANCER PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER. | |
| EP0880967A3 (en) | Nephroprotective drug | |
| DK417889A (en) | USE OF 2-AZABICYCLO (2.2.2.) - CARBOXYLIC ACID DERIVATIVES FOR THE MANUFACTURE OF MEDICAL PRODUCTS FOR THE TREATMENT OF VASCULAR DISEASES | |
| Kukletová et al. | Oxazepam to stomatologic patients who do not cooperate. | |
| Schopflin | Cervical Smears |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |